Wall Street Experts
ver. ZuMIgo(08/25)
Prognozy (mln) dla Madrigal Pharmaceuticals, Inc.
| Okres |
2025-12-31 |
2026-12-31 |
2027-12-31 |
2028-12-31 |
2029-12-31 |
| Przychód (średnia) |
678.04 |
1,107.33 |
1,779.28 |
2,689.68 |
3,805.42 |
| Przychód Δ r/r |
0.00% |
63.31% |
60.68% |
51.17% |
41.48% |
| Przychód (min) |
542.56 |
870.85 |
1,779.28 |
2,199.88 |
3,112.43 |
| Przychód (max) |
834.21 |
1,341.00 |
1,779.28 |
3,230.47 |
4,570.54 |
| EBITDA (średnia) |
406.82 |
664.40 |
1,067.57 |
1,613.81 |
2,283.25 |
| EBIT (średnia) |
406.82 |
664.40 |
1,067.57 |
1,613.81 |
2,283.25 |
| EBIT % |
60.00% |
60.00% |
60.00% |
60.00% |
60.00% |
| Zysk netto (średni) |
-277.95 |
22.73 |
523.58 |
861.01 |
1,565.98 |
| Zysk netto % |
-40.99% |
2.05% |
29.43% |
32.01% |
41.15% |
| EPS (średnia) |
-13.07 |
-1.04 |
18.11 |
40.47 |
73.61 |
| Liczba analityków (Przychody) |
10 |
12 |
11 |
4 |
5 |
| Liczba analityków (EPS) |
12 |
12 |
9 |
4 |
3 |
| symbol |
MDGL |
MDGL |
MDGL |
MDGL |
MDGL |